The studies herein demonstrate that NXP800 reduced basal and HSF1-mediated, HSP90 inhibitor–induced, HSP72 protein expression levels in prostate cancer cell lines, consistent with its mechanistic development rationale and preclinical therapeutic activity in sensitive preclinical models of ovarian cancer (40, 70). This evidence concerns the gene HSF1 and ovarian cancer.